Diligence memo · auto-generated · as of July 2, 2026
Bellicum Pharmaceuticals, Inc
Bellicum Pharmaceuticals, Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Bellicum Pharmaceuticals, Inc operates in Pharmaceuticals, based in HOUSTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Bellicum Pharmaceuticals, Inc has raised $137M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $94M on 2014-08-22.
Most recent recorded round closed around 2014-08-22.
Valuation (modeled)modeled
Provath models Bellicum Pharmaceuticals, Inc at approximately $3.3B (range $306M–$8.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.60× the median modeled value of Series C Pharmaceuticals companies in 2013–2015 (19 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 11.9 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 94% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: Paratek Pharmaceuticals Inc, Turing Pharmaceuticals AG, Seres Health, Inc., Syndax Pharmaceuticals Inc, Intra Cellular Therapies Inc.
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.